Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial-Reference-Cited by-同舟云学术

Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial

Published:2013-10-23 Issue:6 Volume:23 Page:389-396
ISSN:0958-7578
Container-title:Transfusion Medicine
language:en
Short-container-title:Transfusion Med

Author:

Lai Y.-R.¹,Liu R.-R.¹,Li C.-F.²,Huang S.-L.³,Li Q.⁴,Habr D.⁵,Martin N.⁶,Shen Z.-X.⁷

Affiliation:

1. Department of Hematology; The First Affiliated Hospital of Guangxi Medical University; Nanning China

2. Department of Pediatrics; The Affiliated Hospital of Southern Medical University; Guangzhou China

3. Department of Pediatrics; Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Guangzhou China

4. Department of Pediatrics; The Second People's Hospital of Shenzhen; Shenzhen China

5. Novartis Pharmaceuticals Corp; East Hanover NJ USA

6. Novartis Pharma AG; Basel Switzerland

7. Department of Hematology; Ruijin Hospital, Affiliated Hospital of Shanghai Jiao Tong University; Shanghai China

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tme.12077/fullpdf

Reference23 articles.

1. Global epidemiology of globin disorders;Angastiniotis;Annals of the New York Academy of Sciences,1998

2. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia;Cappellini;Blood,2006

3. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of 1744 patients with transfusion-dependent anemias;Cappellini;Haematologica,2010

4. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major; efficacy and safety during 5 years' follow-up;Cappellini;Blood,2011

5. Use of the oral chelator deferiprone in the treatment of iron overload in patients with HbH disease;Chan;British Journal of Haematology,2006

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia;Annals of Medicine;2022-02-01

2. Two trade names of deferasirox (Osveral ? and Exjade?) in reduction of iron overload parameters in major betathalassemia patients: A randomized open labeled clinical trial;CASP J INTERN MED;2022

3. Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children;Hemoglobin;2021-11-10

4. ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects;European Journal of Clinical Pharmacology;2019-11-01

5. Deferasirox for managing iron overload in people with thalassaemia;Cochrane Database of Systematic Reviews;2017-08-15